Envista (NYSE:NVST) Price Target Lowered to $18.00 at UBS Group

Envista (NYSE:NVST) had its price target reduced by UBS Group from $21.00 to $18.00 in a research note published on Monday,Benzinga reports. They currently have a neutral rating on the stock.

Other equities research analysts have also issued research reports about the company. Jefferies Financial Group upped their target price on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd. Needham & Company LLC restated a “hold” rating on shares of Envista in a report on Thursday, March 6th. Bank of America lowered their price objective on shares of Envista from $26.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, April 29th. Morgan Stanley set a $16.00 target price on shares of Envista in a research note on Tuesday, April 15th. Finally, Piper Sandler decreased their price target on shares of Envista from $18.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $20.15.

Envista Stock Performance

NYSE:NVST opened at $17.00 on Monday. The company has a market capitalization of $2.88 billion, a PE ratio of -2.62, a P/E/G ratio of 1.27 and a beta of 0.97. Envista has a fifty-two week low of $14.22 and a fifty-two week high of $23.00. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The company has a 50 day simple moving average of $16.65 and a two-hundred day simple moving average of $19.04.

Envista (NYSE:NVST) last released its earnings results on Thursday, May 1st. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.04. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. The business had revenue of $616.90 million for the quarter, compared to analyst estimates of $608.17 million. During the same quarter in the previous year, the business earned $0.26 earnings per share. Envista’s revenue for the quarter was down 1.1% on a year-over-year basis. Research analysts anticipate that Envista will post 1 earnings per share for the current year.

Institutional Trading of Envista

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UMB Bank n.a. raised its holdings in shares of Envista by 214.4% in the first quarter. UMB Bank n.a. now owns 2,094 shares of the company’s stock valued at $36,000 after purchasing an additional 1,428 shares during the last quarter. Venturi Wealth Management LLC increased its stake in Envista by 528.4% in the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after buying an additional 1,638 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Envista by 30.5% during the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock worth $44,000 after buying an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Envista in the 4th quarter worth approximately $53,000. Finally, Mitsubishi UFJ Trust & Banking Corp bought a new position in shares of Envista in the fourth quarter valued at approximately $86,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.